⟵ Back to Search Results

BGB-A317-Sitravatinib-301

Terminated

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Beigene Study ID info

BGB-A317-Sitravatinib-301

ClinicalTrials.gov ID info

NCT04921358

EudraCT Number info

2022-001779-15

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents